StockNews.AI
EVGN
StockNews.AI
21 days

Evogene Schedules Second Quarter 2025 Financial Results Release

1. Evogene announces Q1 2025 financial results on August 19, 2025. 2. A conference call will be held to discuss the results at 9:00 AM ET. 3. Evogene focuses on AI-driven life-science product development to increase success rates. 4. Three tech engines are used for microbiome and agricultural product advancements. 5. Strategic partnerships enhance product development in various life-science fields.

5m saved
Insight
Article

FAQ

Why Neutral?

Financial result announcements are typically neutral until the results impact forecasts. Previous similar announcements have not consistently driven stock price movements.

How important is it?

The upcoming earnings report might clarify Evogene's financial health, influencing its stock movement.

Why Short Term?

The immediate response from investors will occur post-announcement, impacting sentiment but not long-term trends.

Related Companies

NASDAQ: BMYNASDAQ: ACADNASDAQ: CRIS
Zoom conference call scheduled for August 19, 2025, 9:00 AM ET , /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Tuesday, August 19, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be available online on the company's website a few days after. About Evogene: Evogene Ltd. (Nasdaq, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its subsidiaries, including: Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI; Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI; AgPlenus Ltd. (www.agplenus.com) - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI; Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI. For more information, please visit: www.evogene.com. Contact:[email protected]Tel: +972-8-9311901 Logo: https://mma.prnewswire.com/media/1947468/4576969/Evogene_Logo.jpg SOURCE Evogene WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News